Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11504391
Modified RNA agents with reduced off-target effect
granted -
US 11504403
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
granted -
US 11505574
Modulation of P53 for the treatment of cancer
granted -
US 11505798
Methods and compositions for treating inflammatory diseases
granted -
US 11505790
Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
granted -
US 11504325
Micelles and vesicles for the delivery of glycopeptides
granted -
US 11504394
Targeted ionophore-based metal delivery
granted -
US 11504402
Compositions comprising bacterially derived minicells and methods of using the same
granted -
US 11505620
Methods of detecting plasma kallikrein
granted -
US 11504389
Tau modulators and methods and compositions for delivery thereof
granted -
US 11504385
Proteolysis targeting chimeric molecule, preparation method, and application
granted -
US 11504426
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
granted -
US 11505564
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11505572
Therapeutics for the treatment of glaucoma
granted -
US 11504429
Pharmaceutical compositions comprising meloxicam
granted -
US 11505525
Branched discrete PEG constructs
granted -
US 11505551
Methods for preparing substituted pyridinone-containing tricyclic compounds
granted -
US 11504427
Acoustic and ultrasound-based mechanogenetics and thermogenetics for immunotherapy
granted -
US 11505588
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11505591
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11505575
Cyclic polypeptides for PCSK9 inhibition
granted -
US 11505598
Antibodies to botulinum neurotoxins
granted -
US 11505604
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
granted -
US 11505601
Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum
granted -
US 11505782
Cell-based vehicles for potentiation of viral therapy
granted -
US 11503999
Hyperspectral imaging for detection of Alzheimer's disease
granted -
US 2022370646
PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS
granted -
CA 3217490
MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION
granted -
US 11512112
Peptide for suppressing osteoclast differentiation and use thereof
granted -
US 11510880
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 11512327
Compositions and methods for delivery of AAV
granted -
US 11512128
VEGF/DLL4 binding agents and uses thereof
granted -
US 11510939
RNAs for complement inhibition
granted -
US 11512078
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 11512141
Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
granted -
US 11512052
Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
granted -
US 11510996
Covalent polymer-antigen conjugated particles
granted -
US 11510904
Methods of treating malignant lymphoproliferative disorders
granted -
US 11510872
Nanoparticle-lipid composite carriers and uses thereof
granted -
US 11510927
Pharmaceutical compositions comprising meloxicam
granted -
US 11512312
Treatment of Fuchs' endothelial corneal dystrophy
granted -
US 11512313
Functionally-interdependent shape switching nucleic acid nanoparticles
granted -
US 11512309
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
granted -
US 11512113
Cleavable linker compositions and methods
granted -
US 11512080
CRBN ligands and uses thereof
granted -
US 11512117
Whole avian-origin reverse genetic system and recombinant H5N2 subtype avian influenza virus, vaccine and uses thereof
granted -
US 11512066
Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
granted -
US 11512060
1,2,4-oxadiazole derivatives as immunomodulators
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.